Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer ; volume:11 ; number:1 ; day:11 ; month:6 ; year:2018 ; pages:1-10 ; date:12.2018
Journal of hematology & oncology ; 11, Heft 1 (11.6.2018), 1-10, 12.2018
- Creator
-
D’Souza, Anishka
- Contributor
-
Spicer, Darcy
Lu, Janice
SpringerLink (Online service)
- DOI
-
10.1186/s13045-018-0620-6
- URN
-
urn:nbn:de:101:1-2018082023065566897161
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- D’Souza, Anishka
- Spicer, Darcy
- Lu, Janice
- SpringerLink (Online service)
Other Objects (12)
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Clinicopathological Evaluation of Patients with Hormone Receptor–Positive HER2-Negative Metastatic Breast Cancer Progressing on Endocrine Treatment: A Real-World Retrospective Study from a Regional Cancer Center
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Clinicopathological Evaluation of Patients with Hormone Receptor–Positive HER2-Negative Metastatic Breast Cancer Progressing on Endocrine Treatment: A Real-World Retrospective Study from a Regional Cancer Center
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer